Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00231946 | ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301) | PHASE3 | COMPLETED | 555 | — | — | Sep 1, 2005 | - | Sep 20, 2007 | 59 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| VP4896 | DRUG | - |
Inclusion Criteria: * 60 years of age or older * Diagnosis of probable mild-to-moderate Alzheimer's Disease * On a stable dose of an acetylcholinesterase inhibitor (including, but not limited to: donepezil, galantamine, rivastigmine, and tacrine) for at least 120 days prior to baseline and will lik...